Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Withdrawn 2Terminated 2Active not recruiting 2Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 64Head & Neck 28Thoracic 19Other solid neoplasm 11Tumor-Agnostic 5Gynecologic 3CNS 3Breast 3Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Surgical Procedures, Operative 14Magnetic Resonance Spectroscopy 14Gemcitabine 13Blood Specimen Collection 13Biopsy 13Radiotherapy 12fludarabine 11atezolizumab 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 6selinexor 5liposomal doxorubicin 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cetuximab × Sarcoma × Clear all
NCT06865664 2026-03-16

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
50 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡